Empagliflozin's role in reducing ventricular repolarization heterogeneity: insights into cardiovascular mortality decline from the EMPATHY-HEART trial.

Published in:

Cardiovascular Diabetology, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12933-024-02311-1

By:

• Lauretti, Cristiane;
• Antonio, Graziella L.;
• Fernandes, Ariana E.;
• Stocco, Fernando G.;
• Girardi, Adriana C. C.;
• Verrier, Richard L.;
• Caramelli, Bruno

Publication type:

Article